Blue paper on Alzheimer's disease in China(Simplified Version)

Abstract

With the population aging, the prevalence and mortality rate of Alzheimer's disease (AD) have been rising in China. AD has become one of the biggest threats to population health and social sustainable development. In order to support the Healthy China Initiative and promote health in China, the Blue Paper on Alzheimer's Disease in China was compiled by experts from the National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University; the National Center for Chronic and Noncommunicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention; the National Health Commission Capacity Building and Continuing Education Center; and the China Population and Development Research Center. The epidemiology, diagnosis, treatment, and control of AD and related cognitive disorders in China were reviewed in this blue paper. This work aimed to provide references for the prevention, diagnosis, treatment, and related policy formulation of AD in China. Specifically, the blue paper covered the following topics of AD and related cognitive disorders: (1)epidemiology characteristics; (2)economic burden; (3)impact factors; (4)China Brain Cognitive Health Index; (5)the diagnosis of AD and related cognitive disorders; (6)the treatment of AD and related cognitive disorders; (7)national center for cognitive disorders;(8)community prevention and control; (9)patient care; (10)public health resources for prevention and control.